Therapeutic monoclonal antibodies: Strategies and challenges for biosimilars development

Current Medicinal Chemistry

Volumn 19, Issue 26, 2012, Pages 4445-4450

  Calvo, Begoña ^a   Zuñiga, Leyre ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Biopharmaceuticals; Biosimilars; Comparability; European guidelines; Glycosilation; Immunogenicity; Monoclonal antibodies (mabs); Post translational modifications

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADALIMUMAB; ALEMTUZUMAB; BASILIXIMAB; BEVACIZUMAB; BIOSIMILAR AGENT; CANAKINUMAB; CATUMAXOMAB; CERTOLIZUMAB PEGOL; CETUXIMAB; DENOSUMAB; ECULIZUMAB; ERYTHROPOIETIN; GOLIMUMAB; IBRITUMOMAB TIUXETAN; INFLIXIMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; OFATUMUMAB; OMALIZUMAB; PALIVIZUMAB; PANITUMUMAB; RANIBIZUMAB; RITUXIMAB; TOCILIZUMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNINDEXED DRUG; USTEKINUMAB;

AMINO ACID SEQUENCE; ANTIBODY COMBINING SITE; ARTICLE; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INDICATION; DRUG MANUFACTURE; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; HEAVY CHAIN; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LIGHT CHAIN; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PHYSICAL CHEMISTRY; PROTEIN PROCESSING;

ANTIBODIES, MONOCLONAL; BIOPHARMACEUTICS; BIOSIMILAR PHARMACEUTICALS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, MOLECULAR;

EID: 84868020472     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803251485     Document Type: Article

References (21)

1. Beck, A.; Wurch, T.; Reichert, J.M. 6 Annual Report Antibody Congress 2010. mAbs, 2011,3, 111-132.
2. Carter, P.J. Potent antibody therapeutics by design. Nat. Rev. Immunol., 2006, 6, 343-357.
3. Schneider, C.K.; Kalinke, U. Toward biosimilar monoclonal antibodies. Nat. Biotechnol., 2008, 26, 985 - 990.
4. Barkalow, F. Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies. Available from URL: http://www.citeline.com/wp-content/ uploads/Biosimilar-mABs-in-the-Pipeline.pdf (Accessed July 10, 2012).
5. Reichert, J.M. Marketed therapeutic antibodies compendium. mAbs, 2012, 4, 413-415.
6. Schneider, C.K. EMEA Workshop on biosimilar monoclonal antibodies, 2009. Available from URL: http://www.emea.europa.eu/docs/en-GB/document-library/ Presentation/200 9/11/WC500008473.pdf (Accessed July 10, 2012).
7. Beck, A.; Sanglier-Cianferani, S.; Van Dorsselaer, A. Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry. Anal. Chem., 2012, 84, 4637-4646.
8. Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products containing monoclonal antibodies - non-clinical and clinical issues. EMA/CHMP/BMWP/403543/2010. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideli ne/2012/06/WC500128686.pdf (Accessed July 10, 2012).
9. Committee for Medicinal Products for Human Use (CHMP). Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. EMA/CHMP/BMWP/86289/2010. Available from URL: http://www.ema.europa.eu/ docs/en-GB/document-library/Scientific-guideli ne/2012/06/WC500128688.pdf (Accessed July 10, 2012).
10. Committee for Medicinal Products for Human Use (CHMP). Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues - Guidance on similar medicinal products containing somatropin. EMEA/CHMP/BMWP/94528/2005. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideli ne/2009/09/WC500003956.pdf (Accessed July 10, 2012).
11. Committee for Medicinal Products for Human Use (CHMP). Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical Issues - Guidance on biosimilar medicinal products containing recombinant granulocyte-colony stimulating factor. EMEA/CHMP/BMWP/31329/2005. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-g uideline/2009/09/WC500003955.pdf (Accessed July 10, 2012).
12. Committee for Medicinal Products for Human Use (CHMP). Similar biological medicinal products containing recombinant erythropoietins. EMEA/CHMP/BMWP/ 301636/08. Available from URL: http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideli ne/2010/04/WC500089474.pdf (Accessed July 10, 2012).
13. Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products containing. Biotechnology-derived proteins as active substance: Non-clinical and clinical issues. EMEA/CHMP/BMWP/42832/ 2005. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideli ne/2009/09/WC500003920.pdf (Accessed July 10, 2012).
14. Committee for Medicinal Products for Human Use (CHMP). Guideline on Similar Biological Medicinal Products. CHMP/437/04. Available from URL: http://www.emea.europa.eu/docs/en-GB/document-library/Scientific-guidel ine/2009/09/WC500003517.pdf (Accessed July 10, 2012).
15. Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: Quality issues. EMEA/CHMP/BWP/49348/2005. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideli ne/2009/09/WC500003953.pdf (Accessed July 10, 2012).
16. Committee for Medicinal Products for Human Use (CHMP). Guideline on development, production, characterisation and specifications for monoclonal antibodies and related substances. EMEA/CHMP/BWP/157653/07. Available from URL: http://www.emea.europa.eu/docs/en-GB/document-library/Scientific-g uideline/2009/09/WC500003074.pdf (Accessed July 10, 2012).
17. Committee for Medicinal Products for Human Use (CHMP). ICH guideline S 6 (R1) Preclinical safety evaluation of biotechnology-derived pharmaceuticals. EMA/CHMP/ICH/731268/1998. Available from URL: http://www.ema.europa.eu/docs/en- GB/document-library/Scientific-guideli ne/2009/09/WC500002828.pdf (Accessed July 10, 2012).
18. Committee for Medicinal Products for Human Use (CHMP). Guideline on the clinical investigation of the pharmacokinetics of therapeutic proteins. CHMP/EWP/89249/2004. Available from URL: http://www.ema.europa.eu/docs/en-GB/ document-library/Scientific-guideli ne/2009/09/WC500003029.pdf (Accessed July 10, 2012).
19. Guideline on good pharmacovigilance practices (GVP) Module V - Risk management systems. EMA/838713/2011. Available from URL: http://www.ema.europa. eu/docs/en-GB/document-library/Scientific-guideli ne/2012/06/WC500129134.pdf (Accessed July 10, 2012).
20. Zuñiga, L.; Calvo, B. Biosimilars: pharmacovigilance and risk management. Pharmacoepidemiol. Drug Saf. 2010, 1, 661-669.
21. Calvo, B.; Zuñiga, L. Risk management plan and pharmacovigilance systems. Biopharmaceuticals: biosimilars. In: Risk Management Trends; Nota, Ed.; Intech: Rijeka, 2011; pp. 251-266.